ArticleThe open respiratory medicine journal2014
Inhaled corticosteroids and bone health.
Article in The open respiratory medicine journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Treatment response to indacaterol/glycopyrronium versus salmeterol/fluticasone in exacerbating COPD patients by gender: a post-hoc analysis in the FLAME study.Respiratory research · 2019Trial
- Treadmill walking exercise modulates bone mineral status and inflammatory cytokines in obese asthmatic patients with long term intake of corticosteroids.African health sciences · 2016Trial
- Genetic and epidemiological evidence linking respiratory and musculoskeletal diseases: shared risk factors and intervention windows.Respiratory research · 2026Article
- TIGAR promotes osteogenic differentiation and ameliorates glucocorticoid-induced osteoporosis via autophagy-Nrf2-ROS axis.Genes & diseases · 2026Article
- Asthma and corticosteroids "Frontiers in allergy · 2026Review
- Sex-Specific Safety Signals of Trelegy Ellipta: A FAERS Pharmacovigilance Analysis.Medical sciences (Basel, Switzerland) · 2025Article
- Review
- Nutritional Support of Chronic Obstructive Pulmonary Disease.Nutrients · 2025Review
- Disorders of bone and mineral metabolism in pregnancy and lactation: A case based clinical review.Osteoporosis and sarcopenia · 2025Review
- Effectiveness of biological therapy in severe asthma: a retrospective real-world study.Croatian medical journal · 2025Article
- Prevalence and Factors Influencing Post-Operative Complications following Tooth Extraction: A Narrative Review.International journal of dentistry · 2024Review
- Treating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?Endocrine reviews · 2023Review
- Impact of comorbid conditions on asthmatic adults and children.NPJ primary care respiratory medicine · 2020Review
- Review
- Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures: a narrative review of the literature.International journal of chronic obstructive pulmonary disease · 2019Review
- Alcohol Consumption and Bone Mineral Density in People with HIV and Substance Use Disorder: A Prospective Cohort Study.Alcoholism, clinical and experimental research · 2018Article
- Expression and Regulation of Thymic Stromal Lymphopoietin and Thymic Stromal Lymphopoietin Receptor Heterocomplex in the Innate-Adaptive Immunity of Pediatric Asthma.International journal of molecular sciences · 2018Review
- Osteoporosis in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome.Tuberculosis and respiratory diseases · 2018Article
- Article
- Skeletal Implications of Chronic Obstructive Pulmonary Disease.Current osteoporosis reports · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inhaled corticosteroids (ICS) are the cornerstones in the management of bronchial asthma and some cases of chronic obstructive pulmonary disease. Although ICS are claimed to have low side effect profiles, at high doses they can cause systemic adverse effects including bone diseases such as osteopenia, osteoporosis and osteonecrosis. Corticosteroids have detrimental effects on function and survival of osteoblasts and osteocytes, and with the prolongation of osteoclast survival, induce metabolic bone disease. Glucocorticoid-induced osteoporosis (GIO) can be associated with major complications such as vertebral and neck of femur fractures. The American College of Rheumatology (ACR) published criteria in 2010 for the management of GIO. ACR recommends bisphosphonates along with calcium and vitamin D supplements as the first-line agents for GIO management. ACR recommendations can be applied to manage patients on ICS with a high risk of developing metabolic bone disease. This review outlines the mechanisms and management of ICS-induced bone disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.